Viatris (VTRS) stock analysis and fair value
VTRS · NASDAQ · Healthcare
18,46 US$
▲ +1,10%
Cerne score
29out of 100
Very weak
- Quality29
- Growth31
- Financial strength10
- Valuation33
- Dividends51
In 30 seconds
The business. Healthcare. Sells 14,3 B US$ a year, but is losing money.
The price. No profit over the last 12 months: you can't tell if it's cheap based on earnings.
Strength. Passes 3 of 6 quality checks.
VTRS fair value
Work out what the stock is worth with your own growth, margin and return assumptions. Free during launch.
See the fair valueViatris key numbers
- Market cap
- 21,2 B US$
- Dividend yield
- 2,60%
- Revenue growth
- 3,2%
- a year, over 7 years
- Profit margin
- -24,6%
- Quality checks
- 3/6
Fiscal 2025 financials, as filed with the SEC.
See everything about VTRS on Cerne
- Fair value with your own assumptions
- Every analyst and price target
- 10 years of financials in simple charts
- Dividends, earnings and ratios vs. the sector